Medicare drug discount exemption quietly benefits pharma makers
H.R. 1922 — Ensuring Access to Essential Drugs Act · Filed by Andrew Garbarino (R-NY) · 2 cosponsors · Introduced Mar 6, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill exempts certain oral drugs from Medicare Part D's manufacturer discount program. Specifically, it carves out drugs that received FDA approval as new drugs and have been granted a narrow exception by CMS to be reclassified as non-innovator drugs under Medicaid. The effect is that manufacturers of these drugs would no longer be required to provide the discounts that Part D currently mandates.
Why we flagged it
The bill's operative mechanism is a narrow exemption from mandatory manufacturer discounts in Medicare Part D, benefiting pharmaceutical manufacturers of specific oral drugs at the expense of beneficiary cost-sharing.
What the text implies
- The exemption targets drugs that have received a 'narrow exception' reclassification under Medicaid — a CMS determination that is not defined in this bill and may be opaque to public scrutiny. The criteria for such exceptions are not stated here, creating uncertainty about which drugs qualify.
- The bill does not specify how many drugs currently hold or may obtain such narrow exceptions, making the fiscal impact on Medicare and beneficiary costs difficult to estimate.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers of orally administered drugs with narrow-exception Medicaid reclassific; specialty pharmaceutical companies